Brief Introduction

Jiangsu Bioperfectus Technologies Co., Ltd. is a professional innovative manufacturing enterprise that is oriented in molecular diagnostic techniques. Since established in 2010, Jiangsu Bioperfectus Technologies has helped improve productivity and efficiency for doctors and laboratory researchers worldwide by delivering innovative products and services backed by the highest levels of quality and expertise. We believe our products also provide economic benefits for payers. Of Bioperfectus’s team , one is entitled into ”the recruitment program of global experts“ as distinguished expert; three are rewarded as “double gen talent person”. The company was awarded as “the most potential oversea returnee entrepreneurial company in 2013”. It strives to integrate quality, efficiency, fairness and impartiality into its core culture, and provide the best products and services.

Company Overview

Full name Jiangsu Bioperfectus Technologies Co., Ltd.
Abbreviations sssw
Code 688399
Founded Apr 12th,2010
Listing Dec 5th,2019
Domicile Taizhou, Jiangsu,China
STAR Theme Biomedicine
CSRCSector Manufacturing
Has weighted voting rights structure? No



  2018 2017 2016
Earnings Per Share 1.45 0.97 0.21
R&D expenditure as a % of operating revenue 11.44% 11.43% 11.08%
Operating Revenue 230700330.36 187286185.30 129141955.34
Net Income 63824573.32 42668448.54 8360838.02

Income Statement (Unit: RMB mn)

  2018 2017 2016
Operating Revenue 230.70 187.29 129.14
Operating Costs 42.28 32.45 23.66
Operating Income 73.29 50.56 8.36
Pretax Income 72.97 50.73 13.55
Income Tax 9.15 8.06 5.19
Net Income 63.82 42.67 8.36

Balance Sheet(Unit: RMB mn)

  2018 2017 2016
Current Assets-Total 253.64 250.80 243.62
Non-current Assets-Total 141.92 59.84 42.37
Total Assets 395.56 310.64 285.99
Current Liabilities-Total 55.40 48.12 31.02
Non-current Liabilities-Total 16.06 2.25 3.07
Total Liabilities 71.46 50.37 34.09
Stockholder's Equity
Share Capital 43.96 43.96 43.96
Retained Profits 73.73 9.90 32.08
Minority interests - - -
Total Owners' Equity 324.10 260.28 251.90

Cash Flow Statement (Unit: RMB mn)

  2018 2017 2016
Net Cash Flows-Operating 85.82 61.59 22.09
Net Cash Flows-Investing -75.41 -17.98 -190.71
Net Cash Flows-Financing - -34.29 98.39

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
绍兴闰康生物医药股权投资合伙企业(有限合伙) 15.6 26.61%
Guoqiang Wang 4.95 8.44%
The CID Group 2.86 4.88%
Xu Zhang 2.75 4.69%
Shanghai Tianyi Asset Management Co., Ltd 2.11 3.60%
北京苇渡资本管理有限公司-宁波苇渡一期医疗创业投资合伙企业(有限合伙) 1.98 3.38%
Zhonghua Liu 1.45 2.48%
宁波独角兽投资合伙企业(有限合伙) 1.32 2.25%
嘉兴济峰一号股权投资合伙企业(有限合伙) 1.10 1.87%
泰州硕康企业管理咨询合伙企业(有限合伙) 1.08 1.84%
泰州硕源企业管理咨询合伙企业(有限合伙) 1.08 1.84%
5 Dec 2019

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.